Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS207 in Advanced Malignant Tumor
NCT06022250Phase 1Active, not recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Apr 2026
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JS207 in cancer, sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Dose-limiting toxicity at 2 years, Adverse event at 2 years and 2 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
JS207
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06022250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022250.